The effect of extracellular matrix on the precision medicine utility of pancreatic cancer patient–derived organoids

• DOI: 10.1172/jci.insight.172419
• Publication Date: 2023-12-05T17:00:32Z
• Authors: Jan C. Lumibao; Shira R. Okhovat; Kristina L. Peck; Xiaoxue Lin; Kathryn Lande; Shira Yomtoubian; Isabella Ng; Hervé Tiriac; Andrew M. Lowy; Jingjing Zou; Dannielle D. Engle
• Keywords: Organoid

The use of patient-derived organoids (PDOs) to characterize therapeutic sensitivity and resistance is a promising precision medicine approach, its potential inform clinical decisions now being tested in several large multiinstitutional trials. PDOs are cultivated the extracellular matrix from basement membrane extracts (BMEs) that most commonly acquired commercially. Each site utilizes distinct BME lots may be restricted due availability commercial sources. However, effect different sources BMEs on organoid drug response unknown. Here, we source proliferation, response, gene expression mouse human pancreatic ductal adenocarcinoma (PDA) organoids. Both displayed increased proliferation Matrigel compared with Cultrex UltiMatrix. observed no substantial when were cultured Matrigel, Cultrex, or We also did not observe major shifts across sources, maintained their classical basal-like designation. Overall, found (Matrigel, UltiMatrix) does shift PDO dose-response curves testing results, indicating pharmacotyping robust approach for medicine.